Skip to main content
    C

    CorMedix Inc (CRMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.82
    +0.16 (+3.43%)

    Market Cap: $370.64M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CorMedix Inc (CRMD) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    CorMedix (CRMD) trades at 6.3x trailing earnings and 0.9x sales. Its P/B of 0.8x is below its 5-year median of 3.1x. Its forward P/E is 33.2x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 81.0% lower over the next year. PEG is left out because the growth rate behind it, P/E divided by PEG, is under 2% a year.

    MultipleValue
    P/E (trailing)6.3x
    Forward P/E33.2x
    Price to sales0.9x
    Price to book0.8x
    EV/EBITDA1.0x
    Price to FCF1.2x
    EV/FCF0.5x
    PEGN/A
    FCF yield81.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 77.1% below 3.5x.

    MultipleCurrent5-year median10-year median
    P/B0.8x3.1x3.5x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 105 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 3.0x in 2025 to 891.7x in 2020. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$11.635.4x3.0x2.7x
    2024$8.10N/A11.3x5.9x
    2023$3.76N/A709.6x3.1x
    2022$4.22N/AN/A3.2x
    2021$4.55N/A888.0x2.8x
    2020$7.43N/A891.7x5.4x
    2019$7.28N/A605.7xN/A
    2018$6.45N/A279.8xN/A
    2017$2.50N/A83.8xN/A
    2016$7.65N/A266.7x3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CRMD

    What is CRMD's forward P/E ratio?

    CorMedix has a forward P/E ratio of 33.2x.

    Is CRMD stock overvalued?

    GNG's valuation label for CRMD is Undervalued.

    What is CRMD's price to sales ratio?

    CorMedix has a price to sales ratio of 0.9x.